Literature DB >> 6466158

Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects.

T Tomson.   

Abstract

Fluctuations in plasma carbamazepine concentrations were related to side effects in five epileptics. One patient was receiving only carbamazepine; four were receiving carbamazepine plus phenobarbital sodium or phenytoin sodium. The patients were studied during two 12-hour periods: carbamazepine given (1) twice daily or (2) four times daily. Concomitant medication regimens were kept constant; administration was single-blind. Plasma concentrations of carbamazepine, carbamazepine's epoxide metabolite, phenobarbital, and phenytoin were determined hourly; side effects were assessed simultaneously. Fluctuations in carbamazepine concentrations were 79% +/- 29% higher than trough levels on a twice-daily dosage schedule and 40% +/- 13% higher during four-times-a-day administration. The appearance and intensity of side effects followed the fluctuations in carbamazepine levels and were thus substantially reduced during the four-times-daily regimen. The intrapatient reproducibility of the side effects was good, whereas the thresholds of carbamazepine concentrations at which side effects appeared ranged from 17 to 37 mumole/L.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6466158     DOI: 10.1001/archneur.1984.04050190036011

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  21 in total

1.  Simulated fluctuations in plasma drug concentrations for patients receiving oxcarbazepine or carbamazepine extended-release capsules.

Authors:  Alaa Ahmad; William R Garnett
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

2.  Extended-release formulations of antiepileptic drugs: rationale and comparative value.

Authors:  Emilio Perucca
Journal:  Epilepsy Curr       Date:  2009 Nov-Dec       Impact factor: 7.500

Review 3.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 4.  Drug treatment of epilepsy in the 1990s. Achievements and new developments.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

5.  A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients. Preliminary pharmacokinetic results.

Authors:  A J Loonen; P J Toll; J R Nijdam
Journal:  Pharm Weekbl Sci       Date:  1989-02-24

6.  Slow release carbamazepine in treatment of poorly controlled seizures.

Authors:  S W Ryan; I Forsythe; R Hartley; M Haworth; C J Bowmer
Journal:  Arch Dis Child       Date:  1990-09       Impact factor: 3.791

7.  Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Procaccianti; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

9.  Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.

Authors:  P J McKee; J Blacklaw; E Butler; R A Gillham; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

10.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.